Moderna's COVID-19 vaccine has been available under the FDA's emergency use authorization for individuals 18 years of age and older since Dec. 18, 2020.■
FDA fullyapprovesModerna’s mRNA COVID-19 vaccine, Spikevax, for individuals 18 years of age and older. "The full licensure of Spikevax in the US now joins that in Canada, Japan, the European Union, the UK, Israel, and other countries, where the adolescent indication is also...
Children and adolescents account for approximately 22% of positive COVID-19 cases reported to date, and hospitalizations among this population have recently spiked.3Since July 2020, weekly reported case rates for individuals aged 14 to 17 years have generally mirrored or exceeded rates among adults....
The evidence for whether ivermectin impacts recovery, hospital admissions, and longer-term outcomes in COVID-19 is contested. The WHO recommends its use only in the context of clinical trials. Methods In this multicentre, open-label, multi-arm, adaptive platform randomised controlled trial, we inc...
With unprecedented numbers of individuals under travel restrictions or quarantine, worldwide spread, and no known cure or vaccine yet available, COVID-19 has proven a formidable adversary [12,[13], [14], [15]]. The Ebola Virus Disease (EVD) outbreak of 2014 in West Africa provided valuable...
82/20 on a State of Exception to Prevent and Control the Covid-19 Pandemic", "description": "The presidential decree declares a nationwide \"state of exception.\" The decree grants the government power to limit individuals' freedom of movement and assembly, requisition private property, and ...
For some of these analyses, the controls were simply existing population controls without knowledge of SARS-CoV-2 infection or COVID-19 status, which may bias effect size estimates as some of these individuals may have either become infected with SARS-CoV-2 or developed COVID-19. We perform ...
She has received research grants from Olympus, Ferring and Abbvie. F.K.L.C. has served as an adviser and lecture speaker for Eisai, AstraZeneca, Pfizer, Takeda Pharmaceutical, and Takeda (China) Holdings. The other authors declare no competing interests. Peer review Peer review information ...
Additional non-COVID-19 grants to the institution have also been received from GSK and Minervax. S.A.M. also declares personal honoraria from BMGF unrelated to the manuscript. Resources ihttps://clinicaltrials.gov/ct2/show/NCT04754594 iihttps://clinicaltrials.gov/ct2/show/NCT04765384...
1, Apurv Shah1, Nutcha Wattanchit1, Martha W. Zorn1, Nicholas G. Reich1 ✉ & US COVID-19 Forecast Hub Consortium* Academic researchers, government agencies, industry groups, and individuals have produced forecasts at an unprecedented scale during the COVID-19 ...